Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 1/20 | 0.39 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.34 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.34 |
| ▸ | PPARA | Q07869 | 2/20 | 0.34 |
| ▸ | RARB | P10826 | 2/20 | 0.34 |
| ▸ | METAP2 | P50579 | 2/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 2/20 | 0.30 |
| ▸ | RXRB | P28702 | 1/20 | 0.30 |
| ▸ | RXRG | P48443 | 1/20 | 0.30 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2857001 | 0.87 | PTPN1 (0.31) | RARBRXRARXRBRXRG | |
| SCHEMBL2859703 | 0.83 | VDR (0.58) | VDRSPHK2 | |
| SCHEMBL3283097 | 0.78 | KAT8 (0.39) | SORT1KAT8PPARARARBMETAP2 | |
| SCHEMBL6472378 | 0.76 | — | — | |
| SCHEMBL6472374 | 0.75 | PTGS2 (0.33) | — | |
| SCHEMBL6472376 | 0.75 | PTGS2 (0.33) | — | |
| SCHEMBL6564038 | 0.71 | LCK (0.36) | SORT1KAT8PPARARARBMETAP2 | |
| SCHEMBL6472371 | 0.70 | — | — | |
| SCHEMBL6564995 | 0.70 | LCK (0.35) | SORT1KAT8PPARARARBMETAP2 | |
| SCHEMBL1355572 | 0.67 | SORT1 (0.56) | SORT1KAT8PPARARARBMETAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1456160-B1 | VITAMIN D ANALOGUES | GALDERMA RES & DEV (FR) | 2010-01-20 | — | — | EP | disclosed |
| US-6924400-B2 | Triaromatic vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) | 2005-08-02 | — | — | US | disclosed |
| US-20030195259-A1 | Triaromatic vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195259-A1 | Triaromatic vitamin D analogues | CYP24A1, CYP2R1, VDR | VDR 3/4885SORT1 2046/4885KAT8 3955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.